vs

Side-by-side financial comparison of Tarsus Pharmaceuticals, Inc. (TARS) and WESBANCO INC (WSBC). Click either name above to swap in a different company.

WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $151.7M, roughly 1.7× Tarsus Pharmaceuticals, Inc.). WESBANCO INC runs the higher net margin — 34.5% vs -5.5%, a 40.0% gap on every dollar of revenue. Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 31.9%).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.

TARS vs WSBC — Head-to-Head

Bigger by revenue
WSBC
WSBC
1.7× larger
WSBC
$257.2M
$151.7M
TARS
Higher net margin
WSBC
WSBC
40.0% more per $
WSBC
34.5%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
31.9%
WSBC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
TARS
TARS
WSBC
WSBC
Revenue
$151.7M
$257.2M
Net Profit
$-8.4M
$88.6M
Gross Margin
Operating Margin
-5.3%
Net Margin
-5.5%
34.5%
Revenue YoY
128.4%
Net Profit YoY
63.8%
54.4%
EPS (diluted)
$-0.17
$0.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TARS
TARS
WSBC
WSBC
Q1 26
$257.2M
Q4 25
$151.7M
$265.6M
Q3 25
$118.7M
$261.6M
Q2 25
$102.7M
$260.7M
Q1 25
$78.3M
$193.2M
Q4 24
$66.4M
$162.9M
Q3 24
$48.1M
$150.8M
Q2 24
$40.8M
$147.9M
Net Profit
TARS
TARS
WSBC
WSBC
Q1 26
$88.6M
Q4 25
$-8.4M
$91.1M
Q3 25
$-12.6M
$83.6M
Q2 25
$-20.3M
$57.4M
Q1 25
$-25.1M
$-9.0M
Q4 24
$-23.1M
$49.6M
Q3 24
$-23.4M
$37.3M
Q2 24
$-33.3M
$28.9M
Operating Margin
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
-5.3%
43.2%
Q3 25
-12.2%
39.5%
Q2 25
-21.6%
27.2%
Q1 25
-33.5%
-5.0%
Q4 24
-36.8%
38.0%
Q3 24
-52.3%
29.7%
Q2 24
-81.6%
23.7%
Net Margin
TARS
TARS
WSBC
WSBC
Q1 26
34.5%
Q4 25
-5.5%
34.3%
Q3 25
-10.6%
31.9%
Q2 25
-19.8%
22.0%
Q1 25
-32.1%
-4.7%
Q4 24
-34.8%
30.5%
Q3 24
-48.7%
24.7%
Q2 24
-81.6%
19.5%
EPS (diluted)
TARS
TARS
WSBC
WSBC
Q1 26
$0.88
Q4 25
$-0.17
$0.97
Q3 25
$-0.30
$0.84
Q2 25
$-0.48
$0.57
Q1 25
$-0.64
$-0.15
Q4 24
$-0.57
$0.72
Q3 24
$-0.61
$0.54
Q2 24
$-0.88
$0.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TARS
TARS
WSBC
WSBC
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$343.4M
$4.1B
Total Assets
$562.2M
$27.5B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
$417.3M
$956.1M
Q3 25
$401.8M
$1.0B
Q2 25
$381.1M
$1.2B
Q1 25
$407.9M
$1.1B
Q4 24
$291.4M
$568.1M
Q3 24
$317.0M
$620.9M
Q2 24
$323.6M
$486.8M
Total Debt
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
TARS
TARS
WSBC
WSBC
Q1 26
$4.1B
Q4 25
$343.4M
$4.0B
Q3 25
$335.1M
$4.1B
Q2 25
$332.6M
$3.8B
Q1 25
$342.5M
$3.8B
Q4 24
$224.5M
$2.8B
Q3 24
$237.5M
$2.8B
Q2 24
$252.2M
$2.5B
Total Assets
TARS
TARS
WSBC
WSBC
Q1 26
$27.5B
Q4 25
$562.2M
$27.7B
Q3 25
$534.6M
$27.5B
Q2 25
$495.0M
$27.6B
Q1 25
$500.8M
$27.4B
Q4 24
$377.0M
$18.7B
Q3 24
$376.3M
$18.5B
Q2 24
$376.8M
$18.1B
Debt / Equity
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TARS
TARS
WSBC
WSBC
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
$19.3M
$290.4M
Q3 25
$18.3M
$116.9M
Q2 25
$-29.4M
$105.0M
Q1 25
$-20.7M
$-26.4M
Q4 24
$-22.2M
$211.0M
Q3 24
$-8.7M
$60.7M
Q2 24
$-14.4M
$18.2M
Free Cash Flow
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
$13.0M
$280.0M
Q3 25
$16.3M
$114.9M
Q2 25
$-30.4M
$98.3M
Q1 25
$-21.2M
$-30.7M
Q4 24
$-22.3M
$200.7M
Q3 24
$-8.9M
$56.9M
Q2 24
$-15.4M
$17.3M
FCF Margin
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
8.6%
105.4%
Q3 25
13.8%
43.9%
Q2 25
-29.6%
37.7%
Q1 25
-27.1%
-15.9%
Q4 24
-33.5%
123.2%
Q3 24
-18.6%
37.7%
Q2 24
-37.8%
11.7%
Capex Intensity
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
4.2%
3.9%
Q3 25
1.6%
0.8%
Q2 25
1.0%
2.6%
Q1 25
0.8%
2.2%
Q4 24
0.1%
6.3%
Q3 24
0.6%
2.5%
Q2 24
2.5%
0.6%
Cash Conversion
TARS
TARS
WSBC
WSBC
Q1 26
Q4 25
3.19×
Q3 25
1.40×
Q2 25
1.83×
Q1 25
Q4 24
4.25×
Q3 24
1.63×
Q2 24
0.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TARS
TARS

Segment breakdown not available.

WSBC
WSBC

Net Interest Income$215.4M84%
Noninterest Income$41.8M16%

Related Comparisons